Kornimate/medical-research-clean huggingface dataset:
tar 2 weeks vs 6 weeks post-operative weight-bearing

Conditions: Ankle Osteoarthritis

Summary: the investigators hypothesize that an early 2 week post-operative protocol will have no difference in the successful osseointegration and stability of the total ankle replacement as compared to a delayed 6 week post-operative protocol. the importance of the research is to allow patients who receive a total ankle replacement to bear weight 4 weeks earlier than the current protocol with no negative effect on the osseointegration and stability of the ankle replacement.

the study will be conducted using two groups. the first group will be a retrospective review of charts of 35 patients who received a total ankle replacement porous prosthesis by an orthopedic surgeon at the university of oklahoma health sciences center. this group was received a delayed 6 week post-operative weight-bearing protocol. the second group will be prospective and include patients who will receive the same total ankle replacement porous prosthesis but will be assigned to early 2 weeks post-operative weight-bearing protocol.the retrospective and prospective groups will be age and gender matched. a wright medical infinity total ankle replacement system will be used for both groups. both groups will be assessed at 1 year and 2 years post-operative. this assessment will take place during the post-operative care period and will be conducted as part of their post-operative care by the operating physician.

Eligibility criteria:
retrospective/prospective inclusion criteria: patients who have had a total ankle replacement with the principal investigator from the initiation of his clinical practice from september 2015 to september 2020. had delayed weight-bearing. patients whose age and gender match the retrospective delayed weight-bearing group. retrospective/prospective exclusion criteria: patients who have had total ankle replacement with subsequent development of suture wound infection. patients who have had total ankle replacement with subsequent development of deep infection requiring revision. patient who have had total ankle replacement with subsequent development of peri-prosthetic fractures during surgery or post-op.
using iron supplementation to decrease iron deficiency anemia in infants and young children in india

Conditions: Anemia

Summary: the purpose of this study is to determine the smallest dose of sprinkles, a single-serving package of iron and other micronutrients, to treat infants with iron deficiency anemia in india. results have implications for programs using sprinkles worldwide because lower doses of iron may have fewer side effects.

iron deficiency anemia affects two thirds of children in most developing nations, and even mild anemia can have serious implications for child development. in india, government programs within india have been ineffective in controlling this public health problem due to the lack of effective iron supplements reaching children. our research group developed 'sprinkles', an inexpensive micronutrient supplement which is a single-serve sachet of tasteless powder that contain encapsulated iron and other micronutrients. parents can be easily instructed to mix the contents of one sachet into a bowl of any complementary food. this study is part of a partnership and capacity development between interdisciplinary research groups at the hospital for sick children, university of toronto, canada and the king edward memorial hospital in india, aimed at developing a long-term program of research that will address iron deficiency anemia among infants and young children in india. for sprinkles to be implemented into national programs in india, a comprehensive strategy is needed which includes a single, safe and effective iron dose for the indian population. this specific study is to conduct a community-based, randomized clinical trial in india to determine the appropriate dose of supplementation required for the target age group.

Eligibility criteria:
inclusion criteria: * 6-18 months of age * anemic (hb 70-100g/l) * ingesting weaning food in addition to breast milk * free from major illness (including symptomatic for malaria) and afebrile * living within study area for the next two months * parental consent obtained * only one child per household in the study exclusion criteria: * hb \< 70 or ≥ 100 g/l * not receiving any complementary foods * receiving an iron supplement within two weeks of the date of enrolment * chronic illness * severely malnourished: weight for age z-score \< -3.0 * another child in the household is a subject in this study

Keywords: anemia iron deficiency iron drops iron supplement malnutrition pediatrics
feasibility and safety of allogeneic adipose mesenchymal stem cells (amscs) delivery into kidney allografts procured from deceased donors with high kidney donor profile index (kdpi)

Conditions: Ischemia Reperfusion Injury

Summary: the purpose of this research is to test an investigational drug called adipose mesenchymal stem cells (amscs) for the treatment of ischemia re-perfusion injury (iri) in patients that have had a kidney transplant.


Eligibility criteria:
inclusion criteria: * male or female kidney transplant candidates age 18 and above. * patient is receiving kidney allograft from deceased donor with kdpi\>85%. * ability of subject to give appropriate consent. * females of childbearing potential with agreement to use birth control for six months post-transplant. * approved by the mayo clinic transplant selection committee. * signed authorization for donation of anatomical gifts on file. exclusion criteria: * positive pregnancy test at the time of the kidney offer is called for the potential recipient. * kidney transplant potential recipients with active malignancy (except none melanoma skin malignancies). * patients with previous history of solid organ transplant (heart, lung, intestine, kidney and/or pancreas). * patients with previous history of bone marrow transplant.
non-invasive assessment of intraocular pressure in mps by use of the ocular response analyzer.

Conditions: Mucopolysaccharidosis; Fabry Disease

Summary: the aim of the present study is to compare intraocular pressure (iop) values assessed with ocular response analyzer to the classical gold standard of iop measurement, to goldmann applanation tonometry by mucopolysacchyridosis-, fabry-patients and healthy controls. we want to investigate biomechanical characteristics of the cornea and their influence on the iop-measurements.


Eligibility criteria:
inclusion criteria: * mps i, ii, iv, vi patients with at least grade 3 of corneal clouding (couprie et al.) * fabry patients with cornea verticillata \> grade 1 * age ≥ 12 years * patient is able to comply with the study procedure * patient has consented to be in the trial * ability to fixate a target exclusion criteria: * history of corneal transplantation or refractive surgery * corneal pathologies other than mps-associated corneal opacity * corneal, conjunctival or intraocular inflammation

Keywords: mucopolysaccharidosis fabry disease
cost-effectiveness evaluation of one stage versus two stage exchange for chronically infected total hip and total knee prostheses

Conditions: Chronically Infected Total Hip of Knee Prosthesis

Summary: chronic infection after total joint arthroplasty generally requires implant exchange. two stage exchange is considered as the gold standard procedure. however, some authors suggest that one stage exchange may be as effective. no consensus exists in the current literature. the purpose of the study was to evaluate the cost of both strategies in comparison to their success rate.

the primary criterion will be the cost-utility ratio (icer) at 12 months follow-up. the secondary criteria will be: * quality of life; * pain; * persistence or recurrence of infection; * occurrence of complications ; * necessity for reoperation.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * chronically infected total hip or knee arthroplasty requiring implant exchange * affiliation to a social security system * signed informed consent * effective contraception during all study exclusion criteria: * repeat exchange after failure of a prior treatment for infection * multiple implant infection * infection due to mycobacteria or fungus * pregnancy / breast feeding * patient under judicial protection * impossibility to give informed consent for any reason * participation to another study

Keywords: total hip prosthesis total knee prosthesis chronic infection one stage exchange two stage exchange cost-effectiveness
comparative study evaluating the mobility of transtibial amputee patients using the pro-flex pivot® foot versus a class iii energy storing and returning (esar) prosthetic foot.

Conditions: Amputation

Summary: the pro-flex pivot® is esar prosthetic foot with an innovative technology built around three pillars: 1. the pivot technology: three axes of rotation (upper support, main pivot and lower support) at the ankle, which allow both a movement with more amplitude and closer to the physiological movement of the ankle, and an increase in the power of the ankle, especially in the terminal support phase. 2. the technology of the three carbon blades (plantar, upper and median), including a wider plantar blade, split in the middle of the foot with a separate toe to provide efficiency over the entire length to the big toe, bringing more power to the impulse and more control, but also increased stability until the terminal support phase. 3. an anatomical foot cosmetic, to adapt and optimize the function of the blade: of light manufacture, with an adherent sole for more stability barefoot, it guarantees physiological plantar pressure during the unwinding of the foot. the aim of this study is to demonstrate that compared to a class iii esar foot, the pro-flex pivot® foot improves patient mobility with a validated score.


Eligibility criteria:
inclusion criteria: adult patient (over 18 years of age) * unilateral tibial amputee and fitted for at least 6 months with a class iii esar foot. * regularly using (more than 8 hours/day) a class iii esar foot * functional class (cnedimts indication)1 * insured person. * able to answer questionnaires. * providing informed and written consent to participate in the study. * having a normalized plus-m/fc 12 score less than 50 for vascular amputee and 55 for traumatic amputee and other causes of amputation. * experiencing no discomfort related to the socket indicated by a score ≥ 6 on the numerical scale from 0 to 10 (socket comfort score) exclusion criteria: * bilateral lower limb amputation * femoral amputation * wearing a temporary prosthesis * change of socket or suspension system planned during the study. * change of any functional component as torsion or choc adapter * significant change in the patient's routine activities expected during the study. * progressive associated pathology that may prevent patient follow-up. * associated pathology that may limit the patient's mobility (e.g. disarticulation of the knee, knee pain... ) * no osteointegration patients * lack of consent * adult subject to enhanced protection, deprived of liberty by judicial or administrative decision, hospitalized without consent or admitted to a health or social institution for purposes other than research. * person not affiliated with or a beneficiary of a health insurance plan. * patient unable to understand the study instructions

Keywords: lower limb amputation mobility pro-flex pivot randomized esar foot
usefulness of non tnf usage in ra patients

Conditions: Rheumatoid Arthritis

Summary: the aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. sarilumab treatment for 12 months 2. tocilizmab treatment for 12 months 3. abatacept treatment for 12 months


Eligibility criteria:
inclusion criteria: ・ra patients exclusion criteria: * not ra patients * ra patients who are allergic to the drugs, refused to do this research, or who are pregnant
carotid revascularization with micronet covered stent comparing early neurological outcomes with distal versus proximal eps

Conditions: Patients With Aterosclerotic Carotid Stenosis; Symptomatic Patients (Stenosis > 50%); Asymptomatic Patients (Stenosis ≥80%)

Summary: the siberia study demonstrated a clear advantage of cguard stent implantation over the existing classical stent when using a distal anti-embolic device. at the same time, there is no level 1 evidence for a difference between the proximal and distal anti-embolic device for the cguard stent.


Eligibility criteria:
inclusion criteria 1. consecutive patients 45-80 years old accepted for cas following neurological consultation and qualification for the procedure according to center's routine practice. 2. more than 6-month life expectancy 3. suitable clinical conditions for performing dw-mri 4. written informed consent approved by the ethics committee 5. subject agrees to all required follow-up procedures and visits exclusion criteria: 1. currently enrolled in another investigational device or drug study that has not completed the study or that clinically interferes with the current study endpoints 2. recent surgical procedure within 30-days before or planned surgery within 30-days after the stenting procedure 3. hepatic active disease (bilirubin\> 35 mmol / l) or renal insufficiency (serum creatinine \> 2.5 mg/dl or glomerular filtration rate \<60 ml / min) 4. recent evolving acute stroke within 30-days of study evaluation 5. myocardial infarction within 72 hours prior to carotid stenting procedure (cpk-mb \> 3 times normal) 6. female patients of childbearing potential or known to be pregnant 7. any known factor for potential stroke other than carotid stenosis, such as atrial fibrillation or atrial flutter (paroxysmal, permanent or persistent) or thrombophilia 8. patient on vka or new oral anticoagulants

Keywords: carotid artery stenting. cguard stent. protection device.
comparison of intermittent occlusion and static stretching

Conditions: Muscle Soreness

Summary: to determine changes in vitals caused by intermittent occlusion ( 220 mg ) and to compare the effectiveness of intermittent occlusion and static stretching of the lower limb muscle group in preventing the development of exercise induce muscle soreness

main purpose of this study is to determine changes in vitals caused by intermittent occlusion ( 220 mg ) and to compare the effectiveness of intermittent occlusion and static stretching of the lower limb muscle group in preventing the development of exercise induce muscle soreness. as muscle soreness is very major and basis problem of every individual , specially after enrolling into some physical activity . first consent form will be given to both male and female participants from 18 to 25 years of age and after that par-q questionnaire will be filled for every individual, so that we will check their readiness for the exercise then all the four vitals will measured from every individual .they will randomly assigned by lottery method to intervention group and control group. both group individuals will be exerted by warm up for 5 mints, heel raise in 3 sets for 10 to 15 mints until we get 4 on rpe scale, by asking to hold dumbbells of 2 kg on both of the hands. rate of perceived exertion (rpe) is calculated by borg grading scale .plus, leg circumference, rom of planter and dorsal flexion and numeric pain rating scale (nprs) will be measured for comparison within and between the groups. again vitals will be monitored.

Eligibility criteria:
inclusion criteria: * age limit: 18 -25 years of age. * both males and females. * participants intending to join a fitness or body building program shortly ( the first exercise session would be utilized to induce mild muscle soreness ) * participants ready for physical exertion according to par-q. exclusion criteria: * obesity (body mass index ≥ 30 kg/m2). * skeletal or orthopedic injuries. * known cardiovascular disease. * open wounds. * uncontrolled hypertension (resting brachial blood pressure ≥ 140/90 mmhg). * exercise induced muscle soreness in last 6 months.

Keywords: muscle soreness vital signs intermittent occlusion static stretching
acute efficacy and 6 months follow up after electroconvulsive therapy

Conditions: Depressive Disorder

Summary: the overall aim of the current project is to assess the acute and long term outcome of ect (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting response and remission, side effects and relapse.

patients reffered to electroconvulsive ect are (after written consent) enroled in a research registry. based on (clinician and patient rated) measures of depressive symptoms and overall cognitive function, the short and long-term (6 months) efficacy of ect will be described, and factors predicting response and relapse identified. the duration of possible cognitive impairment and factors predicting cognitive outcome will be examined.

Eligibility criteria:
inclusion criteria: * patients treated with ect for major depression (f31.3-5, f32, f33) at haukeland university hospital or stavanger university hospital after 2013, * written consent to enrolment into the regional register for neurostimulation. exclusion criteria: * ect performed on other indications than major depression. * no consent to the register.
sphenopalatine block in headache in patients with non-traumatic subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage in Adult Patients

Summary: non-traumatic sah, linked in 85% of cases to the rupture of an intracranial aneurysm, is a serious stroke affecting young people. half of all survivors suffer cognitive impairment. the presentation is that of a sudden-onset, isolated headache. this population is exposed to headache during hospitalization, which lasts an average of 13 days. this length of hospitalization is due to the fact that these patients must be monitored during the potential vasospasm period that occurs between days 4 and 14 after sah. the pain associated with sah is a source of discomfort and increased morphine consumption during the icu stay, particularly during the first 10 days. current recommendations call for conventional pain management with a combination of tier 1, 2 and/or 3 analgesics. for headache control, opioids are widely prescribed, sometimes in high doses, with adverse effects, despite efforts to reduce their use. maximum headache pain scores remain high, indicating inadequate pain management. this highlights the urgent need to study alternative opioid-sparing and analgesia strategies for patients with sah.

sphenopalatine block is already used for certain types of facial and cranial pain, and could help save morphine consumption during hospitalization. the sphenopalatine ganglion is a crossroads for parasympathetic, sympathetic and sensory pathways. recently studied in post-puncture dural breaches with promising results, sphenopalatine ganglion block (spgn) may appear as an interesting alternative therapy in the treatment of sah headaches. other advantages of this block are its simplicity, efficacy and the absence of any noticeable adverse effects at the time it is performed. what's more, it is already used routinely in our department, with rapid and effective action. the hypothesis of the trial would be to reduce morphine consumption by at least 50% for patients benefiting from bgsp, for better neurological monitoring and optimal overall pain management in sah.

Eligibility criteria:
inclusion criteria: * ≥ 18 years * non-traumatic sah with or without aneurysm on brain imaging * wfns score 1 and 2 * patient awake and extubated after radiological procedure * patient in pain (en \> 3/10) despite usual level 1 analgesics (paracetamol + acupan) * affiliated with or benefiting from a social security scheme exclusion criteria: * contraindication to sphenopalatine ganglion block (deviated nasal septum, repeated epistaxis, allergy to lidocaine) * patient unable to assess pain by en * persons covered by articles l1121-5 to l1121-8 of the csp and articles 31 to 35 of regulation 536/2014. * participation in other interventional research * patient's refusal to participate * arteriography more than 48 hours old * inaugural headache lasting more than 48 hours * presence of an unsecured vascular malformation at high risk of rupture

Keywords: pain adulte intensive care subarachnoid hemorrhage securing aneurysm lidocaine
evaluation of droplet digital pcr rapid detection method and precise diagnosis and treatment for suspected sepsis

Conditions: Sepsis; Septic Shock

Summary: sepsis is a significant public health concern worldwide, with high morbidity and mortality. with regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. culture-independent molecular diagnostic procedures may represent a promising alternative. in particular, droplet digital pcr (ddpcr) is a novel one-step pcr assay that achieves higher accuracy and sensitivity in detecting causing pathogens in patients with bloodstream infections.


Eligibility criteria:
inclusion criteria: 1.18 years or older 2.meet 2 of 4 sepsis criteria 1. temperature \> 38c or \< 36c 2. heart rate \> 90 bpm 3. respiratory rate \>20 or paco2 \<32mmhg 4. wbc \>12000/µl or \ 10% bands 3.hospitalized patients who have a diagnostic blood culture ordered as standard of care for suspected sepsis 4.informed consent by patient or legal representative. exclusion criteria: 1. refusal to participate in the study or failure to comply with treatment or follow-up time 2. known breastfeeding or pregnancy 3. the researcher believes that there are any conditions (social or medical) that allow subjects to participate is unsafe. for example, severe anemia or high risk of bleeding,etc., which are not suitable for taking peripheral blood for testing 4. participating in other clinical studies

Keywords: digital droplet pcr etiology diagnose
olive polyphenols in cardiovascular prevention

Conditions: Hypertension, Systolic

Summary: the aim of this study is to evaluate whether the use of a commercially available standardized olive extract (tensiofytol®) in individuals with elevated blood pressure 1. leads to a clinically relevant reduction of blood pressure on the short term, 2. leads to a clinically relevant reduction of cholesterol levels, especially ldl, 3. leads to a change in oxidative stress biomarkers. participants will be stratified by sex before randomization to one of the three treatments for 8 weeks: * tensiofytol: 100 mg oleuropein and 20 mg hydroxytyrosol per day * placebo all treatments have an identical shape and color and should be used in the same way (oral intake; 3 capsules/day during dinner). no dietary instructions are given and participants are asked not to change their dietary habits, nor to start other therapies (medication, supplements, slimming diets, extra physical activity, etc.) during their study period. standardized questionnaires are used to obtain information on demographics, dietary habits and side effects. at baseline and after 8 weeks, 27 ml blood is drawn for various biological analyses, and blood pressure, bmi and waist circumference are measured.


Eligibility criteria:
inclusion criteria: * systolic blood pressure ≥ 130 mmhg exclusion criteria: * \<18 jaar * \>76 jaar * smoking * use of nutritional supplements or (chronic) medication\* * triglycerides \> 400 mg/dl * \> 14 alcoholic consumptions/week * chronic illness (e.g. diabetes, atherosclerosis, reumatoid arthritis) * acute infection * current pregnancy or pregnancy wish during the study period * breast feeding * when nutritional supplements were used regularly, participation is allowed after a 10-day wash out period. use of medication will be individually assessed and is permitted if it does not interfere with the used treatments and the patient is stable on the medication.